NovoCure Limited (NASDAQ:NVCR) CEO Asaf Danziger sold 37,272 shares of the business’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $22.01, for a total value of $820,356.72. Following the completion of the transaction, the chief executive officer now owns 776,862 shares in the company, valued at approximately $17,098,732.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Asaf Danziger also recently made the following trade(s):

  • On Wednesday, September 13th, Asaf Danziger sold 35,500 shares of NovoCure Limited stock. The shares were sold at an average price of $22.01, for a total value of $781,355.00.
  • On Tuesday, July 11th, Asaf Danziger sold 7,383 shares of NovoCure Limited stock. The stock was sold at an average price of $19.95, for a total value of $147,290.85.
  • On Monday, July 10th, Asaf Danziger sold 274,359 shares of NovoCure Limited stock. The stock was sold at an average price of $18.07, for a total value of $4,957,667.13.
  • On Wednesday, July 5th, Asaf Danziger sold 155,088 shares of NovoCure Limited stock. The stock was sold at an average price of $18.14, for a total value of $2,813,296.32.
  • On Thursday, July 6th, Asaf Danziger sold 160,138 shares of NovoCure Limited stock. The stock was sold at an average price of $18.14, for a total value of $2,904,903.32.
  • On Monday, June 19th, Asaf Danziger sold 124,720 shares of NovoCure Limited stock. The shares were sold at an average price of $15.51, for a total value of $1,934,407.20.

NovoCure Limited (NVCR) traded down 4.40% during midday trading on Friday, reaching $20.65. The company had a trading volume of 1,138,966 shares. The stock’s market cap is $1.84 billion. NovoCure Limited has a 12 month low of $5.95 and a 12 month high of $22.30. The firm has a 50-day moving average of $19.66 and a 200-day moving average of $14.33.

NovoCure Limited (NASDAQ:NVCR) last announced its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.01). NovoCure Limited had a negative net margin of 75.91% and a negative return on equity of 69.48%. The firm had revenue of $38.38 million for the quarter, compared to analyst estimates of $42.20 million. On average, equities analysts expect that NovoCure Limited will post ($0.77) EPS for the current fiscal year.

WARNING: “NovoCure Limited (NVCR) CEO Asaf Danziger Sells 37,272 Shares” was posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/09/15/novocure-limited-nvcr-ceo-asaf-danziger-sells-37272-shares.html.

A number of institutional investors and hedge funds have recently made changes to their positions in NVCR. Goldman Sachs Group Inc. raised its position in NovoCure Limited by 6,617.7% during the second quarter. Goldman Sachs Group Inc. now owns 4,988,007 shares of the medical equipment provider’s stock valued at $86,293,000 after purchasing an additional 4,913,755 shares in the last quarter. FMR LLC raised its position in NovoCure Limited by 50.4% during the second quarter. FMR LLC now owns 6,888,120 shares of the medical equipment provider’s stock valued at $119,165,000 after purchasing an additional 2,309,559 shares in the last quarter. Vanguard Group Inc. raised its position in NovoCure Limited by 40.5% during the second quarter. Vanguard Group Inc. now owns 4,283,862 shares of the medical equipment provider’s stock valued at $74,111,000 after purchasing an additional 1,235,922 shares in the last quarter. Frontier Capital Management Co. LLC acquired a new position in NovoCure Limited during the second quarter valued at approximately $14,308,000. Finally, PointState Capital LP acquired a new position in NovoCure Limited during the second quarter valued at approximately $5,744,000. Institutional investors and hedge funds own 36.84% of the company’s stock.

Several analysts recently weighed in on NVCR shares. Zacks Investment Research upgraded NovoCure Limited from a “sell” rating to a “buy” rating and set a $19.00 target price for the company in a research note on Thursday, June 29th. ValuEngine raised NovoCure Limited from a “sell” rating to a “hold” rating in a report on Saturday, June 3rd. Mizuho assumed coverage on NovoCure Limited in a report on Wednesday, September 6th. They issued a “buy” rating and a $25.00 target price for the company. BidaskClub cut NovoCure Limited from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Finally, Deutsche Bank AG reissued a “hold” rating and issued a $19.00 target price (up from $18.00) on shares of NovoCure Limited in a report on Monday, July 17th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $20.00.

About NovoCure Limited

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Insider Buying and Selling by Quarter for NovoCure Limited (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.